Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Date:4/23/2009

NEW YORK, April 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to be its interim Chairman and Chief Executive Officer, replacing Michael S. Weiss, effective immediately.

Mr. Tarnok, age 54, has served on Keryx's Board of Directors since September 2007. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director -- US Manufacturing. From 2000-2007, Mr. Tarnok served as Senior Vice President, Finance in Pfizer's US Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including contracting, trade management, forecasting of significant product launches and Sarbanes-Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathw
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 2014 Deep Research Report ... research report on the Global Palmitic Acid industry. ... Acid, basic information, including definition, classification, application, industry ... analysis, etc. , For international and China ... market in China and other countries or ...
(Date:11/26/2014)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... detection of foodborne pathogens, today announced that Paul G. ... Annual Healthcare Conference on December 2, 2014 at 4:30pm ... Palace in New York, NY . ... its operations, strategies and prospects may be discussed. To listen ...
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 /PRNewswire/ ... company focused on developing diagnostic tests for cancer and other ... study will be presented at the Science for Business BioWin ... Belgium . The data come from VolitionRx,s lung ... the Pneumology department of the Centre Hospitalier Universitaire (CHU) de ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
Breaking Biology Technology:Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... be participating in the Barclays Capital 2010 Global Healthcare Conference in Miami, Fla. , on March 23, 2010 , at 8:30 a.m. Eastern Time .   , ... , ... ... ...
... for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece , Turkey ... systems at the core of life science research. , ... ... ...
... patient cases using magnetic resonance-guided heat (laser interstitial ... cancer recurrence after surgical removal of the prostate ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... salvage radiation treatment and are often presented with ...
Cached Biology Technology:Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 3The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 2The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... to study addicted,smokers, a new drug that attaches ... implicated in nicotine addiction ,may help studies ... and schizophrenia.,Developed by UC Irvine Transdisciplinary Tobacco Use ... selective binding agent,that identifies specific areas of the ...
... may be precipitated by a "traffic jam" within neurons ... and structures in the cells, according to new studies ... models of Alzheimer's disease and in human brain samples ... breakdown in neurons that appears to prevent the normal ...
... Scientists at Joslin Diabetes Center have discovered one reason why ... developing type 2 diabetes later in life. In studies of ... pancreas's ability to later secrete enough insulin in response to ... don't have delivery of enough nutrients from the mother to ...
Cached Biology News:Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Neuronal 'traffic jam' marks early Alzheimer's disease 2Neuronal 'traffic jam' marks early Alzheimer's disease 3Neuronal 'traffic jam' marks early Alzheimer's disease 4Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 2Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 3Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 4
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Feline IL-5...
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
Biology Products: